Correction to: Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa

Affiliations

¹ Department of Dermatology, Stanford University School of Medicine, Stanford, CA, USA.
² Veterans Affairs Medical Center, Palo Alto, Stanford, CA, USA.
³ Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
⁴ Mission Dermatology Center, Department of Dermatology, Children's Hospital of Orange County, University of California Irvine, Rancho Santa Margarita, CA, USA.
⁵ Pediatric Skin Research, Coral Gables, FL, USA.
⁶ Division of Dermatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
⁷ Krystal Biotech, Inc., 2100 Wharton St, Suite 701, Pittsburgh, PA, 15203, USA.
⁸ Krystal Biotech, Inc., 2100 Wharton St, Suite 701, Pittsburgh, PA, 15203, USA. skrishnan@krystalbio.com.

Published Erratum

M Peter Marinkovich et al. Am J Clin Dermatol. 2025 Jul.

. 2025 Jul;26(4):637.

doi: 10.1007/s40257-025-00956-6.

¹ Department of Dermatology, Stanford University School of Medicine, Stanford, CA, USA.
² Veterans Affairs Medical Center, Palo Alto, Stanford, CA, USA.
³ Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
⁴ Mission Dermatology Center, Department of Dermatology, Children's Hospital of Orange County, University of California Irvine, Rancho Santa Margarita, CA, USA.
⁵ Pediatric Skin Research, Coral Gables, FL, USA.
⁶ Division of Dermatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
⁷ Krystal Biotech, Inc., 2100 Wharton St, Suite 701, Pittsburgh, PA, 15203, USA.
⁸ Krystal Biotech, Inc., 2100 Wharton St, Suite 701, Pittsburgh, PA, 15203, USA. skrishnan@krystalbio.com.

No abstract available

Erratum for

Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa.
Marinkovich MP, Paller AS, Guide SV, Gonzalez ME, Lucky AW, Bağcı IS, Agostini B, Fitzgerald K, Chen S, Chen H, Conner MM, Krishnan SM. Marinkovich MP, et al. Am J Clin Dermatol. 2025 Jul;26(4):623-635. doi: 10.1007/s40257-025-00942-y. Epub 2025 Apr 12. Am J Clin Dermatol. 2025. PMID: 40220208 Free PMC article. Clinical Trial.